Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era.
Bedognetti
Davide
D
Zoppoli
Gabriele
G
Sertoli
Mario Roberto
MR
Zanardi
Elisa
E
Blandini
Pietro
P
Uccellini
Lorenzo
L
Boccardo
Francesco
F
Andreoli
Giovanni Battista
GB
Ghio
Riccardo
R
Racchi
Omar
O
Ferrarini
Manlio
M
De Maria
Andrea
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects; D005260:Female; D006509:Hepatitis B / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology; D006510:Hepatitis B Antibodies / Q000097:blood*; D006512:Hepatitis B Core Antigens / Q000276:immunology*; D006801:Humans; D016867:Immunocompromised Host; D008223:Lymphoma / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D016036:Seroepidemiologic Studies
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D000069283:Rituximab